Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Total Liabilities (2016 - 2025)

Dexcom (DXCM) has disclosed Total Liabilities for 16 consecutive years, with $3.6 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 17.98% to $3.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 billion through Dec 2025, down 17.98% year-over-year, with the annual reading at $3.6 billion for FY2025, 17.98% down from the prior year.
  • Total Liabilities for Q4 2025 was $3.6 billion at Dexcom, down from $4.8 billion in the prior quarter.
  • The five-year high for Total Liabilities was $4.8 billion in Q3 2025, with the low at $2.5 billion in Q1 2021.
  • Average Total Liabilities over 5 years is $3.7 billion, with a median of $3.9 billion recorded in 2023.
  • The sharpest move saw Total Liabilities skyrocketed 64.31% in 2021, then fell 17.98% in 2025.
  • Over 5 years, Total Liabilities stood at $2.9 billion in 2021, then grew by 12.75% to $3.3 billion in 2022, then grew by 28.71% to $4.2 billion in 2023, then increased by 4.43% to $4.4 billion in 2024, then dropped by 17.98% to $3.6 billion in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $3.6 billion, $4.8 billion, and $4.8 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.